雌激素受体阳性（ER +）/ HER2阴性（HER2-）乳腺癌被称为内质型乳腺癌，是最常见的亚型，约占所有乳腺癌病例的70％。无论病情扩散的程度如何，内质型乳腺癌的标准首选治疗是内分泌治疗（ET）与细胞周期依赖性激酶（CDK）4/6抑制剂的联合应用。患者经历多次内分泌治疗（ET）±靶向治疗，直到出现内分泌耐药后才会提出姑息化疗方案。了解内分泌耐药机制并开发新的内分泌治疗选项是当前临床研究的主要挑战之一。另一个极有兴趣的领域是改善内分泌治疗后的治疗方法。其中，抗体药物联合物（ADCs）的开发非常有前途，其中一些药物很快可能成为治疗无法治愈的疾病的治疗武器。本综述文章概述了目前可用的ER + / HER2-转移性乳腺癌治疗选项，并广泛讨论了晚期临床开发的新方法。版权所有©2023作者。由Elsevier Ltd.出版。保留所有权利。

Estrogen receptor-positive (ER+)/HER2-negative (HER2-), the so-called luminal-type breast cancer, is the most frequent subset, accounting for around 70% of all breast cancer cases. Endocrine therapy (ET) combined with cyclin-dependent kinases (CDK) 4/6 inhibitors is the standard first option in the management of advanced luminal breast cancer independently of disease extension. Classically, patients undergo multiple lines of ET ± targeted treatments until endocrine resistance occurs and palliative chemotherapy is proposed. Understanding endocrine resistance mechanisms and development of novel ET options is one of the main challenges in current clinical research. Another area of utmost interest is the improvement of post-endocrine therapeutic approaches. Among others, the development of antibody-drug conjugates (ADCs) is very promising, and some of these drugs will probably soon become a part of the therapeutic arsenal against this incurable disease. This review paper provides an overview of currently available treatment options in ER+/HER2- metastatic breast cancer and extensively discusses new approaches in late clinical development.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.